ArticleResearch square2026
Glial and Neuronal Alzheimer's Disease-Related Alterations Reproduced in Human Induced Pluripotent Stem Cells With Presenilin-1 Mutation.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background: A pathogenetic role of glial cells has been established virtually in all neurodegenerative disorders. In Alzheimer's disease (AD), together with β-amyloid deposition and the formation of fibrillary tangles, neuroinflammation contributes to neuronal dysfunction associated with the disease. Thus, selective control of glial cell activation becomes part of the multifactorial therapeutic strategies in AD. Astrocytes and microglia are highly heterogeneous in their morphology and physiology, and this diversity underlies their distinct functional states in the central nervous system. In AD, they exhibit dynamic and stage-dependent pathological phenotypes during disease onset and progression. In this context, investigating the disease-associated glia signature would provide significant progress in understanding pathological mechanisms and in the development of beneficial treatments. The use of human induced pluripotent stem cells (iPSCs) to study CNS cell alterations during brain pathologies greatly improves the possibility of identifying human- and cell-specific changes likely contributing to AD progression. Methods: Here we used isolated glia cultures and neuron/glia cocultures derived from iPSC carrying a mutation in the presenilin-1 (PSEN1) gene to investigate AD-related microglia and astrocyte impairments and their contribution to neuronal degeneration. Results: Microglia from AD iPSCs showed compromised functional properties while astrocytes exhibited a predominant fibroblast-like phenotype and increased expression of inflammatory markers. Consistently, transcriptomic derangement for reactive phenotype-related genes, correlating with cell morphology, allowed to well distinguish AD astrocytes from control cells. We finally observed that glia-specific AD-related changes affected some neuronal properties in mixed neuron/glia cocultures, while the presence of the mutation in both cell population triggered a dramatic neuronal damage, involving neuronal network degradation, synaptic alterations and impaired electrophysiological properties. On the other hand, the replacement of AD with healthy glia was not sufficient to protect from neurodegeneration, suggesting the pivotal role of mutated PSEN1 in neurons. Conclusions: We herein succeeded in reproducing crucial AD-related changes in iPSC-derived
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.